Glionova AB is a privately-held development stage biopharmaceutical company based in Stockholm, Sweden. We are dedicated to the development of innovative therapies for difficult-to-treat cancers using the company's unique expertise and proprietary technology. Our lead product, GLN-1001, is being developed for treating patients suffering from glioblastoma (GBM), the most common and most aggressive primary brain tumor. GBM is a devastating disease with marginal life expectancy and limited treatment options, necessitating the development of conceptually new therapeutic strategies.
We are developing a novel therapy aiming to selectively and efficiently kill GBM cells by targeting a newly discovered vulnerability of the cancer cells, namely catastrophic vacuolization. Our lead compound GLN-1001, currently in preclinical development, has been shown to efficiently deplete cancer cells without apparent effects on tissue. Through further development, GLN-1001 has the potential to provide improved clinical benefit for patients in dire need of new therapeutic options.
The company's management consists of a dynamic team of academic scientists, experienced drug developers, and business professionals.